As a new-type foreign trade service provider driven by both technology transformation and foreign trade services, HiSiaddi has built a "1+2+3+4=1" service system and can supply raw materials of Echinacea Purpurea Extract from multiple well-known original manufacturers.
Boasting R&D capabilities, HiSiaddi has conducted multiple rounds of on-site inspections of Echinacea Purpurea Extract manufacturers through technological cooperation with factories, gaining objective and in-depth understanding of various brands. We regularly analyze different Echinacea Purpurea Extract manufacturers for clients to help them select matching products. Below is a brand selection support case.
Please contact HiSiaddi customer service if you require more comparative analysis of brands and product models.
The buyer is NaturaVital AG based in Zurich, Switzerland, a leading mid-to-high-end dietary supplement enterprise in Switzerland with products sold in Swiss national high-end chain pharmacies, German-Swiss organic supermarkets and private health institutions. Its core products include Echinacea soft capsules, children’s oral liquids and herbal granules. Raw materials must comply with EU EC396 standard covering 226 pesticide residue items, USP, FSSC22000, KOSHER and EUDR traceability regulations. The annual planned procurement volume of Echinacea Purpurea Extract totals 12.2 tons, divided into two varieties: medicinal capsule powder and cold-water instant modified powder for oral liquids, with mandatory indicators: Cichoric acid ≥4.0% (HPLC), total polyphenols ≥8.5%, no exogenous starch or dextrin added.
The client entered China’s procurement market for the first time and had no understanding of domestic leading Echinacea brands, product grading and model parameters. It successively contacted five mainstream domestic manufacturers including Conba Innotai, Xi’an Ruibo, Shaanxi Sinuote, Hunan Huacheng and Tiandiyuan Biological for quotations and samples. Each manufacturer only promoted its own product lines: while no manufacturer slandered competitors, they would not voluntarily provide objective explanations of peer products’ strengths, applicable scenarios and weaknesses for business reasons. The client received 5 sample batches with widely varying indicators and a quotation range exceeding 42%, unable to distinguish high-end pharmaceutical-grade raw materials from ordinary food-grade bulk materials. Sample small-scale trials encountered consecutive issues including unstable batch content, mismatched water solubility for oral liquid production lines and incomplete EU compliance supporting documents, consuming 45 days on sample testing and formula debugging and delaying new product launch progress. The client entrusted HiSiaddi to horizontally dissect all brands relying on industry resources and conduct neutral brand selection.
HiSiaddi compiled complete archives of five domestic leading Echinacea brands, sorting out strengths, applicable terminal scenarios and inherent defects neutrally from dimensions including raw material traceability, production processes, product models, compliance qualifications, without bias toward any manufacturer.
· Core Model 1: EP40 Pharmaceutical Grade (Cichoric acid 4.0% HPLC, total polyphenols 8.8%), ten-thousand mu self-owned GAP Echinacea planting base in Gansu, low-temperature resin refining, full SGS EU pesticide residue testing, compatible with hard capsule mass production;
· Core Model 2: FD Water-Soluble Modified Powder (Cichoric acid 3.8%, cold-water instant dissolution), cyclodextrin inclusion process, specially developed for oral liquids;
· Strengths: Production in pharmaceutical GMP workshops, inter-batch difference ≤±2%, complete EUDR & REACH compliance documents;
· Weaknesses: High customized minimum order quantity (≥500kg per single order), high unit price, high cost for small-batch sample trials.
· Core Model: RB-PH4 Refined Pharmaceutical Powder (Cichoric acid 4.1%, total polyphenols 9.0%), self-owned GAP planting base in Chifeng, Inner Mongolia, supercritical low-temperature extraction, two sub-models for conventional pharmaceutical grade and organic grade with dual certifications;
· Strengths: Flexible small-batch sample trial support (minimum 5kg order), US NOP + EU organic dual certifications for organic grade, excellent powder fluidity compatible with automatic capsule filling;
· Weaknesses: Limited dedicated modified product lines for oral liquids, requiring additional customized modification procedures.
· Core Models: SNT-10:1 Crude Extract Powder, 2% conventional cichoric acid powder, mainly food-grade bulk materials, high-temperature water extraction process, raw materials purchased from scattered farmers;
· Strengths: Low quotation, sufficient spot inventory;
· Weaknesses: No finalized pharmaceutical-grade product stably reaching 4.0% cichoric acid standard, no EU organic qualifications, loose internal pesticide residue control, incompatible with Swiss high-end formulation access standards, only suitable for low-end solid beverages.
· Core Model: HC-35 Dietary Grade (Cichoric acid 3.5%, total polyphenols 7.2%), medium purification process;
· Strengths: Stable supply for Southeast Asian and Australian health food clients, fast lead time;
· Weaknesses: Core indicators fail to meet the client’s mandatory ≥4.0% cichoric acid threshold, no cold-water instant modified models for oral liquids.
· Core Model: TDY-4% Cichoric Acid General Powder, mixed water & ethanol extraction;
· Strengths: Sufficient spot inventory of standard general products;
· Weaknesses: No targeted GAP raw material sources, large fluctuations in active ingredient content across batches, incomplete English full-set COA compliance documents, difficult to complete Swiss import filing.
Combining the client’s dual production lines for capsules and oral liquids, strict EU compliance requirements, demand for small-batch sample trials followed by bulk replenishment and annual framework supply of mid-to-high-end raw materials, three poorly matched brands (Sinuote, Huacheng, Tiandiyuan) were eliminated, with two mid-to-high-end brands confirmed: Conba Innotai and Xi’an Ruibo, and three finalized products selected:
1. Conba Innotai EP40 Pharmaceutical-Grade Powder (Model 1): Exclusively for soft capsule production lines, stably containing 4.02%–4.08% cichoric acid, no filling excipients, full-process GMP control, complete EU import filing documents, suitable for the client’s large-batch mass production of core capsule products;
2. Conba Innotai FD Water-Soluble Modified Powder (Model 2): Specially developed for the client’s children’s oral liquid line, fully soluble in cold water at room temperature with no precipitation or stratification after 90 days of storage at 4°C, starch/dextrin-free β-cyclodextrin modification, perfectly resolving the earlier precipitation and stratification issues of oral liquids;
3. Xi’an Ruibo RB-PH4 Organic Pharmaceutical Powder (Model 3): Exclusive raw material for the client’s high-end organic dietary granule line, dual organic certifications for the brand’s premium organic new product series, flexible small-batch replenishment to offset Conba’s high minimum order quantity threshold.
HiSiaddi coordinated notarized 50g sample delivery from both brands, synchronously arranging full physical & chemical testing plus 226-item pesticide residue testing by Swiss third-party laboratories. All three raw material varieties passed pre-review by Swiss drug regulatory authorities. The client first conducted small-batch trial procurement: 1.8 tons of Conba EP40, 1.2 tons of FD water-soluble powder and 0.8 tons of Ruibo organic RB-PH4. Full compliance was achieved in small-scale production trials, with capsule weight deviation and oral liquid stability fully meeting formulation standards. After successful trial order implementation, NaturaVital of Switzerland signed a long-term procurement framework for an annual volume of 12.2 tons: a total of 8.7 tons of two Conba varieties and 3.5 tons of Ruibo organic model, split into 12 monthly production batches. Leveraging differentiated products from the two brands, the client simultaneously launched conventional and organic product lines, with new products successfully distributed across all high-end pharmacy channels in Switzerland.
Most domestic plant extract manufacturers focus on promoting their own products and avoid objectively introducing competitors’ strengths. High-end overseas pharmaceutical enterprises lack familiarity with domestic brand tiering: listed pharmaceutical brands focus on high-standard pharmaceutical-grade raw materials, full-industry-chain Northwest brands prioritize flexible customization, and most small and medium-sized factories produce low-end bulk materials. Asymmetric information easily leads to poor brand selection and procurement risks. From a neutral third-party perspective, HiSiaddi horizontally dissects advantages and disadvantages of all brands, accurately matching product models according to terminal formulation scenarios, helping clients avoid procurement risks of low-end bulk materials and efficiently complete high-end raw material selection and implementation.
Please contact HiSiaddi customer service if you require more comparative analysis of brands and product models.
+86-13120989737 
info@hisiaddi.com 
English
